Syncom Formulations (India) Limited (SYNCOMF) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Syncom Formulations (India) Limited stock ₹9.69, price ₹21.19, that is 54.3% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Syncom Formulations (India) Limited
SYNCOMF · NSEFar too expensive (fair value 54% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
48‑month range ₹5.00 – ₹26.77 · fair‑value band ₹5.45 – ₹15.51 · the ₹21.19 price screens above the ₹9.69 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether Syncom Formulations (India) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments.
Show moreShow less
The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms.
It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers its pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent.
Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
Stock analysis
Syncom Formulations (India) Limited (SYNCOMF) currently trades at ₹21.19, while our model-based Fair Value estimate is ₹9.69, 54% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹16.31 per share, and 1 of the 24 models we run sit above the ₹21.19 price.
Bear case: the Asset-Based group reads lowest at ₹2.25, and 23 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹5.45 (bear) to ₹15.51 (bull), the price of ₹21.19 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Syncom Formulations (India) Limited reported revenue of ₹4.9B in FY2026 versus ₹2.2B in FY2022, a compound +22.4%/yr. Reported net income was ₹764M in FY2026, compounding +40.2%/yr from FY2022.
Key figures
Market cap ₹20.0B (≈ $212M) Micro · P/E ratio 21.8 · P/S ratio 3.85 · EPS (TTM) ₹0.9700 · Net margin 17.2% · Return on equity 20.2% · Return on assets (EBIT) 7.8% (5-year average) · Operating margin 19.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 106% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −54%, SYNCOMF screens richer than that median.
Fair Value models
All 24 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
SYNCOMF screens overvalued: fair value 54% below the price. Compare with Merck KGaA →
Compare Syncom Formulations (India) Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- Stock screener with 62 metrics
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs SYNCOMF |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs SYNCOMF |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs SYNCOMF |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs SYNCOMF |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs SYNCOMF |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs SYNCOMF |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs SYNCOMF |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs SYNCOMF |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs SYNCOMF |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs SYNCOMF |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Syncom Formulations (India) Limited (SYNCOMF) overvalued or undervalued?
What is the fair value of SYNCOMF?
What is the quality score of SYNCOMF?
What is the price target for Syncom Formulations (India) Limited (SYNCOMF)?
What is the Syncom Formulations (India) Limited stock forecast for 2026?
What is the revenue of Syncom Formulations (India) Limited (SYNCOMF)?
What growth is priced into Syncom Formulations (India) Limited (SYNCOMF)?
What discount rate (WACC) does the fair value of SYNCOMF use?
What is a reverse DCF?
How much growth has Syncom Formulations (India) Limited (SYNCOMF) delivered so far?
How fast is the sector of Syncom Formulations (India) Limited (SYNCOMF) growing?
What is the free cash flow yield of Syncom Formulations (India) Limited (SYNCOMF)?
What is the intrinsic value of Syncom Formulations (India) Limited (SYNCOMF)?
Is Syncom Formulations (India) Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SYNCOMF?
How much is Syncom Formulations (India) Limited worth?
What do the bullish and bearish scenarios say about SYNCOMF?
What is the P/E ratio of SYNCOMF?
How solid is the balance sheet of Syncom Formulations (India) Limited (SYNCOMF)?
How far is SYNCOMF from its 52-week high?
Which stocks are comparable to Syncom Formulations (India) Limited?
Is Syncom Formulations (India) Limited stock attractive at the current price?
How is the fair value of SYNCOMF calculated?
Is it still worth investing in stocks now?
What is the share price of Syncom Formulations (India) Limited (SYNCOMF)?
What should I pay attention to with Syncom Formulations (India) Limited right now?
Where does the earnings growth of Syncom Formulations (India) Limited (SYNCOMF) come from?
Key figures of Syncom Formulations (India) Limited
How large is the market capitalisation of Syncom Formulations (India) Limited (SYNCOMF)?
What is the P/S ratio of Syncom Formulations (India) Limited (SYNCOMF)?
What are the earnings per share of Syncom Formulations (India) Limited (SYNCOMF)?
What is the net margin of Syncom Formulations (India) Limited (SYNCOMF)?
What is the return on equity of Syncom Formulations (India) Limited (SYNCOMF)?
What is the EBIT return on assets of Syncom Formulations (India) Limited (SYNCOMF)?
What is the operating margin of Syncom Formulations (India) Limited (SYNCOMF)?
How fast is revenue growing at Syncom Formulations (India) Limited (SYNCOMF)?
How fast are earnings growing at Syncom Formulations (India) Limited (SYNCOMF)?
How much net cash does Syncom Formulations (India) Limited (SYNCOMF) hold?
Watch Syncom Formulations (India) Limited in the live analysis
One click puts Syncom Formulations (India) Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.